{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:10:07Z","timestamp":1751296207393,"version":"3.41.0"},"reference-count":54,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Hepatitis B virus may reactivate in patients with chronic hepatitis C treated with direct\u2010acting antivirals. The aim of this study was to investigate the risk of hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) reactivation in<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u00a0+\u00a0hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>)\u2010co\u2010infected patients with compensated liver cirrhosis treated with paritaprevir\/ombitasvir\/ritonavir, dasabuvir with ribavirin. We reviewed prospectively gathered data from a national cohort of 2070 hepatitis C virus patients with compensated liver cirrhosis who received reimbursed paritaprevir\/ombitasvir\/r, dasabuvir with ribavirin for 12\u00a0weeks from the Romanian National Health Agency during 2015\u20102016. Twenty\u2010five patients in this cohort were<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s antigen positive (1.2%); 15 untreated with nucleotide analogues agreed to enter the study. These patients were followed up:<jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>monthly, serology for<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>viral load at baseline,<jats:styled-content style=\"fixed-case\">EOT<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>at 12\u00a0weeks. Hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>)\u2010co\u2010infected patients were all genotype 1b and 52% females, with a median age of 60\u00a0years (51\u00a0\u00f7\u00a074); 76% were pretreated with peginterferon\u00a0+\u00a0ribavirin; 72% were with severe necroinflammatory activity on FibroMax assessment; 40% presented comorbidities; and all were<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>e antigen negative. Hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>)<jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>response rate was 100%. Hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>)\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>viral load was undetectable in 7\/15 (47%) before therapy, and for the other 8 patients, it varied between below 20 and 867\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL. Five patients (33%) presented virological reactivation (&gt;2 log increase in<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>levels) during therapy. One patient presented with hepatitis associated with<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>reactivation, and two started anti\u2010<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>therapy with entecavir. Hepatitis B virus (<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>) virological reactivation was present in 33% in our patients. Generally,<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>elevations were mild (&lt;20\u00a0000\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL); however, we report one case of hepatitis associated with<jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>reactivation.<\/jats:p>","DOI":"10.1111\/jvh.12872","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T14:52:40Z","timestamp":1517669560000},"page":"834-841","source":"Crossref","is-referenced-by-count":4,"title":["Risk of hepatitis B virus reactivation in hepatitis B virus\u00a0+\u00a0hepatitis C virus\u2010co\u2010infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir\/r\u00a0+\u00a0dasabuvir\u00a0+\u00a0ribavirin"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-7971","authenticated-orcid":false,"given":"C. M.","family":"Preda","sequence":"first","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. P.","family":"Popescu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Virology Department Victor Babes Hospital Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baicus","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Internal Medicine Department Colentina Hospital Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oproiu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Voiosu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Internal Medicine Department Colentina Hospital Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Diculescu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Negreanu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology Department Emergency Universitary Hospital Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gheorghe","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sporea","sequence":"additional","affiliation":[{"name":"UMF Timisoara, Gastroenterology &amp; Hepatology Department Timisoara Emergency Hospital Timisoara Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Trifan","sequence":"additional","affiliation":[{"name":"UMF Gr T Popa Iasi, Gastroenterology &amp; Hepatology Department Gastroenterology &amp; Hepatology Institute Iasi Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ceausu","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Virology Department Victor Babes Hospital Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Proca","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Manuc","sequence":"additional","affiliation":[{"name":"UMF \u201cCarol Davila\u201d Gastroenterology &amp; Hepatology Department Clinic Fundeni Institute Bucharest Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13086"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.15403\/jgld.2014.1121.244.hbv","article-title":"How far we are towards eradication of HBV infection","volume":"24","author":"Voiculescu M","year":"2015","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12081"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i42.11931"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-010-0060-4"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i40.14559"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01941.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328358b0bb"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.02.08012-en","article-title":"Trends in hepatitis B incidence in Romania, 1989\u20102005","volume":"13","author":"Pitigoi D","year":"2008","journal-title":"Euro Surveill"},{"key":"e_1_2_8_11_1","first-page":"479","article-title":"Epidemiological and laboratory features of chronic hepatitis B cases in the interval 2010\u20102013","volume":"118","author":"Luca AS","year":"2014","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"e_1_2_8_12_1","first-page":"373","article-title":"The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006\u20132008","volume":"19","author":"Gheorghe L","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_8_13_1","first-page":"43","article-title":"A cross\u2010sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South\u2010Eastern regions of Romania","volume":"19","author":"Voiculescu M","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)30803-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.22072"},{"key":"e_1_2_8_16_1","first-page":"165","article-title":"Clinical and therapeutical importance of HBV genotyping in Romania","volume":"1","author":"Constantinescu I","year":"2008","journal-title":"J Med Life"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.11.002"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27337"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26400"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082013000500002"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20944"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05384.x"},{"key":"e_1_2_8_23_1","article-title":"Real\u2010world efficacy and safety of ombitasvir, paritaprevir\/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis","author":"Preda CM","year":"2017","journal-title":"Liver Int"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13790"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.05.049"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30048-1"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.15403\/jgld.2014.1121.263.iac","article-title":"Real\u2010life use of 3 direct\u2010acting antiviral regimen in a large cohort of patients with genotype\u20101b HCV compensated cirrhosis","volume":"26","author":"Gheorghe L","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.15403\/jgld.2014.1121.262.rom","article-title":"Position paper on treatment of hepatitis C in Romania, 2017. Part one","volume":"26","author":"Gheorghe L","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3066"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13496"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12784"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12754"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.05.021"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12737"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14177"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12919"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx028"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1325869"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0377"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29135"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13771"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13985"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29109"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/cid\/ciw507","article-title":"No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir\u2010sofosbuvir for hepatitis C virus infection","volume":"63","author":"Sulkowski MS","year":"2016","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.06.023"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.02.026"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082010000900006"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.216"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90766-8"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02990102"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01627.x"},{"key":"e_1_2_8_55_1","first-page":"305","article-title":"Effectiveness of entecavir treatment and predictive factors for virologic response","volume":"106","author":"Preda CM","year":"2014","journal-title":"Rev Esp Enferm Dig"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12872","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T14:28:32Z","timestamp":1751293712000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/jvh.12872"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12872","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2018,2,21]]}}}